Thursday, 10. February 2022

**Physicians Session**
14:00 - 14:15  
*OP01 - Opening*
*Chair: Nicolaus Kröger, DE*
*Chair: John Gribben, GB*

**EBMT/EHA on-demand [Pre-recorded session]**
14:00 - 20:30  
*OD*

**YA01 - EBMT Trainee Committee & YoungEHA Ambassadors**
*Chair: Claire Horgan, GB*
*Chair: Eleni Gavriilaki, GR*

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 - 14:16</td>
<td>Science for the future: The basic science behind the cure</td>
<td>Michael Hudecek, DE</td>
<td>A1</td>
</tr>
<tr>
<td>14:16 - 14:31</td>
<td>What is real in the real world? A balanced walk through the data jungle: Current indications,</td>
<td>Anna Sureda, ES</td>
<td>A1</td>
</tr>
<tr>
<td></td>
<td>trial Vs real world data, the importance of reporting</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:31 - 14:53</td>
<td>Infused, what now? How to learn to detect and treat adverse events: CRS &amp; ICANS</td>
<td>Roberta Di Blasi, FR</td>
<td>A1</td>
</tr>
<tr>
<td>14:53 - 14:57</td>
<td>Closing remarks</td>
<td></td>
<td>A1</td>
</tr>
</tbody>
</table>

**Physicians Session**
14:15 - 15:15  
*PS01 - Session 1 - Clinical Indications*
*Chair: Thomas Cluzeau, FR*
*Chair: Claire Roddie, GB*

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:15 - 14:27</td>
<td>Approved and emerging CAR-Ts in ALL</td>
<td>Mohamad Mohy, FR</td>
<td>A1</td>
</tr>
<tr>
<td>14:27 - 14:39</td>
<td>Approved and Emerging CARTs in Non-Hodgkin’s Lymphoma</td>
<td>Anna Sureda, ES</td>
<td>A1</td>
</tr>
<tr>
<td>14:39 - 14:51</td>
<td>Emerging CAR-Ts in CLL</td>
<td>John Gribben, GB</td>
<td>A1</td>
</tr>
<tr>
<td>14:51 - 15:03</td>
<td>Approved and emerging CAR-Ts in MM</td>
<td>Hermann Einsele, DE</td>
<td>A1</td>
</tr>
<tr>
<td>15:03 - 15:15</td>
<td>Q&amp;A</td>
<td></td>
<td>A1</td>
</tr>
</tbody>
</table>

**Physicians Session**
15:25 - 16:25  
*PS02 - Session 2 - New Clinical Data and Trial Pipeline*
*Chair: Fabio Ciceri, IT*
*Chair: Annette Künkele, DE*

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:25 - 15:37</td>
<td>CD19 and GD2 CAR T in Pediatric Cancer</td>
<td></td>
<td>A1</td>
</tr>
</tbody>
</table>
**EBMT-EHA 4th European CAR T-Cell Meeting February 10 - 12, 2022 Virtual**

**Scientific program**

**PS02-1**
**Speaker:** Franco Locatelli, IT

**PS02-2**
**Factors associated with outcomes of CD19-targeted immunotherapy**
**Speaker:** Cameron Turtle, US

**PS02-3**
**Update from 'HCB' CAR T trials**
**Speaker:** Julio Delgado, ES

**PS02-4**
**Update from 'UKW' CAR T trials**
**Speaker:** Michael Hudecek, DE

**PS02Q**
**Q&A**

---

**Best Abstracts**
16:30 - 17:00

**BA01 - Best abstracts & Awards**

**Chair:** John Gribben, GB
**Chair:** Nicolaus Kröger, DE

**BA01-1**
**Discovery of Synthetic Cell States for Cancer Immunotherapy**
**Speaker:** Franziska Blaeschke, US

**BA01-2**
**Microbial Short-chain Fatty Acids Enhance CAR T Cell-mediated Cancer Immunotherapy**
**Speaker:** Maik Luu, DE

**BA01-3**
**Tumor-on-a-Chip for Efficacy and Safety Assessment of CAR-T Cell Therapy**
**Speaker:** Tengku Ibrahim Maulana, DE

**BA01Q**
**Q&A**

---

**Break**
17:00 - 17:30

**B1 - Break, Poster Viewing, Visit Exhibition**

---

**Keynote**
17:30 - 18:15

**KN01 - Keynote Lecture 1**

**Chair:** Sonia Guedan, ES
**Chair:** Michael Loschi, FR

**KN01-1**
**CAR T update and charting a way forward**
**Speaker:** Carl June, US

**KN01Q**
**Q&A**

---

**Satellite Symposium**
18:30 - 19:15

**SS01 - Satellite symposium by Janssen | Transforming the landscape of multiple myeloma with CAR T-cell therapies**

**Chair:** Philippe Moreau, FR
### Introduction

*Speaker:* Philippe Moreau, FR  
18:30 - 18:32

### SS01-2

**How are CAR T-cell therapies changing the landscape in multiple myeloma?**

*Speaker:* Kwee Yong, GB  
18:32 - 18:47

### SS02-3

**Practical considerations for CAR T-cell therapy in patients with multiple myeloma**

*Speaker:* Inger Nijhof, NL  
18:47 - 19:02

### Panel discussion with Q&A

19:02 - 19:15

### Virtual Poster Tours

19:20 - 19:50

#### PT01 - Virtual Poster Tour 1 | Pre-clinical Data

*Chair:* Michael Hudecek, DE

| PT01-1 | Multi-antigen-Targeting of MM Using TCR and CAR Engineered T Cells  
*Oral Presenter:* Tassilo L A Wachsmann, NL  
19:20 - 19:23
| PT01-2 | Ribonucleoprotein-mediated CRISPR Prime Editing Enables Precision Editing in Primary T-cells  
*Oral Presenter:* Karl Petri, US  
19:23 - 19:26
| PT01-3 | CARAMBA  
*Oral Presenter:* Elisabeth Ehrend, DE  
19:26 - 19:29
| PT01-4 | CAR T-cells Targeting Aspergillus fumigatus  
*Oral Presenter:* Michelle Seif, DE  
19:29 - 19:32
| PT01-5 | Functional Activity of CIK Cells Plus Blinatumomab and CARCIK-CD19 Cells  
*Oral Presenter:* Silvia Zaninelli, IT  
19:32 - 19:35

#### PT01Q

**Q&A**  
19:35 - 19:50

### Virtual Poster Tours

19:20 - 19:50

#### PT02 - Virtual Poster Tour 2 | Clinical data

*Chair:* Ibrahim Yakoub-Agha, FR

| PT02-1 | Superiority of Axicabtagene Ciloleucel in Second-line LBCL in the Elderly  
*Oral Presenter:* Tom van Meerten, NL  
19:20 - 19:23
| PT02-2 | Molecular CAR-T Cell Tracking in Real-world Patients with Severe ICANS  
*Oral Presenter:* Susanna Carolina Berger, DE  
19:23 - 19:26
| PT02-3 | CAR-HEMATOTOX: Risk-stratifying Infectious Complications and Disease Progression in r/r LBCL  
*Oral Presenter:* Kai Rejeski, DE  
19:26 - 19:29
**PT02-4**  Prophylactic Corticosteroids with Axi-Cel in R/R LBCL: ZUMA-1 Cohort 6  
*Oral Presenter*: Olalekan O. Oluwole, US

**PT02-5**  Healthcare Decision-making in Patients with DLBCL: CAR-T vs non-CAR-T  
*Oral Presenter*: Lorna Warwick, CA

**PT02Q**  Q&A

---

**Virtual Poster Tours**  
20:00 - 20:30

**PT03 - Virtual Poster Tour 3 | Pre-clinical Data**  
*Chair*: Michael Hudecek, DE

**PT03-1**  Multimodal Imaging of CAR T Cells in a Solid Tumor  
*Poster Presenter*: Rita Pfeifer, DE

**PT03-2**  PD-1/PD-L1 Axis in CAR-T Cell Function  
*Poster Presenter*: Irene Andreu-Saumell, ES

**PT03-3**  CXCR4-modified CD33.CAR-CIK with Enhanced Bone Marrow Homing in AML  
*Poster Presenter*: Marta Biondi, IT

**PT03-4**  Engineered T Cells Overcoming Rejection by Antibodies (CORA-T Cells)  
*Poster Presenter*: Anna Christina Dragon, DE

**PT03-5**  CAR-Tregs for Systemic Lupus Erythematosus  
*Oral Presenter*: Matteo Doglio, IT

**PT03Q**  Q&A

---

**Virtual Poster Tours**  
20:00 - 20:30

**PT04 - Virtual Poster Tour 4 | Clinical Data**  
*Chair*: Ibrahim Yakoub-Agha, FR

**PT04-1**  Sleeping Beauty-engineered CARCIK-CD19 in B-ALL Patients  
*Oral Presenter*: Chiara F. Magnani, CH

**PT04-2**  CD19 CAR-T Cells with HPK1 Knockout Might Be Safe and Effective for Adult r/r B-ALL  
*Oral Presenter*: Yu Wang, CN

**PT04-3**  CARTITUDE-2 Cohort A Update: Ciltacabtagene Autoleucel in Progressive, Multiple Myeloma  
*Oral Presenter*: Michel Delforge, BE

**PT04-4**  Locally Produced Novel BCMA CART Cells  
*Oral Presenter*: Nathalie Asherie, IL

**PT04-5**  Patient and Caregiver Experiences of CAR-T at a UK Centre  
*Oral Presenter*: Charlotte Stenson, GB
PT04Q  Q&A  20:15 - 20:30
Friday, 11. February 2022

Keynote
09:00 - 09:45

**KN02 - Keynote Lecture 2**
*Chair: Dirk Busch, DE
Chair: Sara Mastaglio, IT*

**KN02-1** Strategies to increase tumor elimination with engineered T cells
*09:00 - 09:30
Speaker: Stanley Riddell, US*

**KN02Q** Q&A
*09:30 - 09:45*

Nurses Session
09:00 - 09:10

**OPN1 - Introduction & Welcome**
*Chair: Michelle Kenyon, GB
Chair: Erik Aerts, CH*

Nurses Session
09:10 - 09:40

**NG00 - The Nice Experience**
*Chair: Michelle Kenyon, GB
Chair: Erik Aerts, CH*

**NG00-1** Introducing the CART programme into practice – the Nice experience
*09:10 - 09:30
Speaker: Alizee Soldati, FR*

**NG00Q** Q&A
*09:30 - 09:40*

Nurses Session
09:45 - 10:50

**NG01 - Nurses Session I - Overview**
*Chair: Michelle Kenyon, GB
Chair: Erik Aerts, CH*

**NG01-1** Overview of immune system and its role in fighting cancer
*09:45 - 10:03
Speaker: Antonia Mueller, CH*

**NG01-2** Overview of clinical studies in haematological malignancies
*10:03 - 10:21
Speaker: Adrian Bloor, GB*

**NG01-3** Paediatric indications and experience
*10:21 - 10:39
Speaker: Daphna Hutt, IL*

**NG01Q** Q&A
*10:39 - 10:50*
### Physicians Session

09:50 - 10:50

**PS03 - Session 3 - Next-Gen CAR-T Therapy**

*Chair: Álvaro Urbano Ispizua, ES*

*Chair: Chiara Bonini, IT*

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>PS03-1</td>
<td>Engineering Next-Generation CAR-T Cells for Cancer Therapy</td>
<td>09:50 - 10:02</td>
</tr>
<tr>
<td></td>
<td><em>Speaker: Yvonne Chen, US</em></td>
<td></td>
</tr>
<tr>
<td>PS03-2</td>
<td>In vivo CAR T cell generation</td>
<td>10:02 - 10:14</td>
</tr>
<tr>
<td></td>
<td><em>Speaker: Christian Buchholz, DE</em></td>
<td></td>
</tr>
<tr>
<td>PS03-3</td>
<td>iPSC-derived CAR-T cells: the road to clinical translation</td>
<td>10:14 - 10:26</td>
</tr>
<tr>
<td></td>
<td><em>Speaker: Maria Themeli, NL</em></td>
<td></td>
</tr>
<tr>
<td>PS03-4</td>
<td>CAR-T therapy and the microbiome</td>
<td>10:26 - 10:38</td>
</tr>
<tr>
<td></td>
<td><em>Speaker: Christoph Stein-Thöringer, DE</em></td>
<td></td>
</tr>
<tr>
<td>PS03Q</td>
<td>Q&amp;A</td>
<td>10:38 - 10:50</td>
</tr>
</tbody>
</table>

**Break**

10:50 - 11:25

*Break, Poster Viewing, Visit Exhibition*

### Industry Theatre

10:50 - 11:20

**IT02 - Industry Theatre (Auditorium 1): The Future of CART | by Novartis**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>IT02-1</td>
<td>Advancing Manufacturing process in CART</td>
<td>10:50 - 11:00</td>
</tr>
<tr>
<td></td>
<td><em>Speaker: Bernd Eschgfaeller, CH</em></td>
<td></td>
</tr>
<tr>
<td>IT02-2</td>
<td>The Next Generation of CART</td>
<td>11:00 - 11:10</td>
</tr>
<tr>
<td></td>
<td><em>Speaker: Aby Buchbinder, US</em></td>
<td></td>
</tr>
<tr>
<td>IT02-3</td>
<td>Interactive Q&amp;A discussion</td>
<td>11:10 - 11:20</td>
</tr>
</tbody>
</table>

**Nurses Session**

11:20 - 13:05

**NG02 - Nurses Session II - Treatment Updates**

*Chair: John Murray, GB*

*Chair: Ruth Clout, GB*

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>NG02-1</td>
<td>CART in lymphoma</td>
<td>11:20 - 11:45</td>
</tr>
<tr>
<td></td>
<td><em>Speaker: Ulrich Jäger, AT</em></td>
<td></td>
</tr>
<tr>
<td>NG02-2</td>
<td>CART in myeloma</td>
<td>11:45 - 12:05</td>
</tr>
<tr>
<td></td>
<td><em>Speaker: Maaike de Ruijter, NL</em></td>
<td></td>
</tr>
<tr>
<td>NG02-3</td>
<td>Off the shelf/Allo CART</td>
<td>12:05 - 12:25</td>
</tr>
<tr>
<td></td>
<td><em>Speaker: Jürgen Kuball, NL</em></td>
<td></td>
</tr>
<tr>
<td>NG02-4</td>
<td>CART, IEC, BITE – what does the new technology mean for patients with solid malignancies</td>
<td>12:25 - 12:45</td>
</tr>
<tr>
<td></td>
<td><em>Speaker: Fiona Thistlethwaite, GB</em></td>
<td></td>
</tr>
</tbody>
</table>
**Scientific program**

**EBMT-EHA 4th European CAR T-Cell Meeting**

**February 10 - 12, 2022 Virtual**

**NG02Q**

**Q&A**

12:45 - 13:05

**Best Abstracts**

11:25 - 11:55

**BA02 - Best abstracts flash talks**

*Chair:* Monica Casucci, IT  
*Chair:* André Baruchel, FR

**BA02-1**

**Split-signaling Dual CD138/CD38 CAR T-cells to Safely Target Multiple Myeloma**  
*Speaker:* Jort van der Schans, NL  
11:25 - 11:30

**BA02-2**

**Epigenome Editing Enables PD1 Silencing in CAR T Cells**  
*Speaker:* Maria Silvia Roman Azcona, DE  
11:30 - 11:35

**BA02-3**

**In vitro Myeloid Differentiation Is Halted by Activated CAR-T Cells**  
*Speaker:* Maria Luisa Palacios-Berraquero, ES  
11:35 - 11:40

**BA02Q**

**Q&A**

11:40 - 11:55

**Physicians Session**

12:00 - 13:00

**PS04 - Session 4 - CAR-T in Oncology**

*Chair:* Francis Ayuk, DE  
*Chair:* Karin Straathof, GB

**PS04-1**

**T4 Immunotherapy of Head and Neck Cancer**  
*Speaker:* John Maher, GB  
12:00 - 12:12

**PS04-2**

**Approaches to increase the therapeutic index of CAR-T cells in solid tumours**  
*Speaker:* Sonia Guedan, ES  
12:12 - 12:24

**PS04-3**

**Chemokine receptor-enhanced CAR-T therapy**  
*Speaker:* Sebastian Kobold, DE  
12:24 - 12:36

**PS04-4**

**Augmenting CAR-T therapy in solid tumors through immunomodulation**  
*Speaker:* Robert Zeiser, DE  
12:36 - 12:48

**PS04Q**

**Q&A**

12:48 - 13:00

**Break**

13:00 - 13:45

**B3 - Lunch Break, Poster Viewing, Visit Exhibition**

**Industry Theatre**

13:10 - 13:40

**IT03 - Industry Theatre (Auditorium 1): Kite as innovators in CAR T-cell therapy manufacturing and delivery**

**IT03-1**

**Kite as innovators in CAR T-cell therapy manufacturing and delivery**

13:10 - 13:25
Speaker: Dick Sundh, AU

Satellite Symposium
13:45 - 14:30 A1
SS02 - Satellite symposium by Bristol Myers Squibb | CAR T cell therapy: current status and new perspectives
Chair: Pere Barba, ES
SS02-1 Welcome and Introduction
SS02-2 From innovation to implementation: CAR T for r/r LBCL
   Speaker: Stephan Mielke, SE
SS02-3 The future of cellular therapy in MM
   Speaker: Salomon Manier, FR
SS02Q Q&A and discussion | All faculty, moderated by Pere Barba |
   Closing remarks

Nurses Session
14:30 - 16:00 A2
NG03 - Nurses Session III - Patient Experience
Chair: Ruth Clout, GB
Chair: John Murray, GB
NG03-1 Patient experience - interview
   Speaker: Guy Bouguet, FR
   Speaker: Philippe Piedigrossi, IT
NG03-2 The role of charities in patient care
   Speaker: Kristina Modic, SI
NG03-3 Working with the third sector to enhance patient care
   Speaker: Andreas L.G. Reimann, DE
NG03-4 What supportive care do patients need?
   Speaker: Natacha Bolanos, ES
NG03Q Q&A

Physicians Session
14:35 - 15:35 A1
PS05 - Session 5 - Interactive pros / cons
Chair: Jürgen Kuball, NL
Chair: Martina Schuessler-Lenz, DE
Chair: Attilio Bondanza, GB
PS05-1 Allo vs. Auto CAR-T: Auto
   Speaker: Michael Schmitt, DE
PS05-2 Allo vs. Auto CAR-T: Allo
   Speaker: Reuben Benjamin, GB
PS05Q1 Debate
PS05-3  What is the future of CAR T-cell production? Academic point-of-care (POC) vs. centralized industrial manufacturing | pro POC  
Speaker: Ibrahim Yakoub-Agha, FR  
15:05 - 15:10

PS05-4  What is the future of CAR T-cell production? Academic point-of-care (POC) vs. centralized industrial manufacturing | pro CIM  
Speaker: Ulrike Köhl, DE  
15:10 - 15:15

PS05Q2  Debate  
15:15 - 15:35

**Physicians Session**
15:40 - 16:40

**PS06 - Session 6 - New CAR-T Indications**
Chair: Michael Hudecek, DE  
Chair: Raffaella Greco, IT

PS06-1  In vivo CART therapy for fibrosis  
Speaker: Jonathan Epstein, US  
15:40 - 15:52

PS06-2  CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus  
Speaker: Andreas Mackensen, DE  
15:52 - 16:04

PS06-3  Opportunities and challenges of immunotherapeutic approaches of HBV cure  
Speaker: Ulrike Protzer, DE  
16:04 - 16:16

PS06-4  Engineering Specific T cells to Modulate Adverse Immune Responses: Driving CARs to BARs  
Speaker: David Scott, US  
16:16 - 16:28

PS06Q  Q&A  
16:28 - 16:40

**Break**
16:00 - 16:30

**NB - Break, Poster Viewing, Visit Exhibition**

**Nurses Session**
16:30 - 17:50

**NG04 - Nurses Session IV - Treatment outcome influencers**
Chair: Erik Aerts, CH  
Chair: Michelle Kenyon, GB

NG04-1  ‘Prehab to rehab’ – optimising health and wellbeing  
Speaker: Aimee Green, GB  
16:30 - 16:50

NG04-2  Training and education – how to fill the gaps by working together  
Speaker: Julia Ruiz Pato, ES  
16:50 - 17:10

NG04-3  Late effects – expected and unexpected  
Speaker: Patrick Hayden, IE  
17:10 - 17:30

NG04-4  Case study  
17:30 - 17:45
Scientific program

Speaker: Daniela Beyer-Bontognali, CH

NG04Q  Q&A  17:45 - 17:50

Break
16:40 - 17:00  A1

B4 - Break, Poster Viewing, Visit Exhibition

Physicians Session
17:00 - 17:45  A1

PS07 - Session 7 - CAR-T: New Standard of Care in Lymphoma?
Chair: Christian Chabannon, FR
Chair: Marie Jose Kersten, NL
PS07-1  Second line treatment in aggressive B-NHL: CAR-T or autologous transplant?  17:00 - 17:15
Speaker: Mehdi Hamadani, US

PS07-2  Round table  17:15 - 17:45
Speaker: Ulrich Jäger, AT
Speaker: Bertram Glass, DE
Speaker: Guy Bouguet, FR
Speaker: Anna Sureda, ES

Keynote
17:50 - 19:10  A1

KN03 - Panel Chairs & Keynote Lecture 3
Chair: Ibrahim Yakoub-Agha, FR
Chair: Michael Hudecek, DE
Chair: Maria Themeli, NL
Chair: Hermann Einsele, DE

KN03-all  Where do we stand and where do we go with CAR-T?  17:50 - 18:20
Discussion
Speaker: Michel Sadelain, US

KN03-1  Antigen sensitivity of CAR T cells  18:20 - 18:50
Speaker: Michel Sadelain, US

KN03Q  Q&A  18:50 - 19:10

Nurses Session
17:55 - 18:05  A2

NGCL - Closing remarks
Chair: Erik Aerts, CH
Chair: Michelle Kenyon, GB

Physicians Session
19:15 - 20:15  A1

PA01 - Things you need to know about CAR T-cell therapy: talking about CAR-T cell therapy in lay language | Roundtable
Chair: Natacha Bolaños, ES
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>PA01-1</td>
<td>Clinician Perspective</td>
<td>Marie Jose Kersten, NL</td>
<td>19:15</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Yavor Pertov, BG</td>
<td>19:15</td>
</tr>
<tr>
<td>PA01-2</td>
<td>Patient perspective</td>
<td>Jonathan Clark, GB</td>
<td>19:15</td>
</tr>
<tr>
<td>PA01-3</td>
<td>Nurse Perspective</td>
<td>Mairéad Ni Chonghaile, IE</td>
<td>19:15</td>
</tr>
<tr>
<td>PA01-4</td>
<td>Psychologist Perspective</td>
<td>Surabhi Chaturvedi, GB</td>
<td>19:15</td>
</tr>
</tbody>
</table>
Saturday, 12. February 2022

**Physicians Session**
08:30 - 09:45

**PS08 - Session 08 - Clinical management**
*Chair:* Marion Subklewe, DE  
*Chair:* Hans Scheurer, NL

PS08-1 **MAS/ICANS - CRS**  
*Speaker:* Claire Roddie, GB  
08:30 - 08:47

PS08-2 **Cytopenia/Infections**  
*Speaker:* Max Topp, DE  
08:47 - 09:04

PS08-3 **COVID-19 and CAR-T Therapy**  
*Speaker:* Arnon Nagler, IL  
09:04 - 09:21

PS08-4 **Specific organ tox (Cardiac)**  
*Speaker:* Daniel Chen, GB  
09:21 - 09:33

PS08Q **Q&A**  
09:33 - 09:45

**Physicians Session**
08:30 - 09:45

**PS09 - Session 09 - CAR T Technology Forum**
*Chair:* Javier Briones, ES  
*Chair:* Miriam Alb, DE

PS09-1 **Gene transfer and genomic safety**  
*Speaker:* Zoltán Ivics, DE  
08:30 - 08:42

PS09-2 **Safety & Efficacy Models for CAR-T**  
*Speaker:* Monica Casucci, IT  
08:42 - 08:54

PS09-3 **Machine learning in single cell genomics**  
*Speaker:* Fabian Theis, DE  
08:54 - 09:06

PS09-4 **T cell subset selection for CAR engineering**  
*Speaker:* Luca Gattinoni, DE  
09:06 - 09:18

PS09D **Debate**  
09:18 - 09:45

**Satellite Symposium**
09:45 - 10:30

**SS04 - Satellite Symposium by Gilead Kite on R/R DLBCL highlights in CAR T from ASH 2021, Implications for current 3L+ practice**

SS04-1 **Introduction to the symposium**  
09:45 - 09:47

SS04-2 **What have we learned about the pivotal CAR T trials?**  
*Speaker:* Tanya Siddiqi, US  
09:47 - 09:56

SS04-3 **What learnings are there in the real-world use of CAR T?**  
*Speaker:* Roch Houot, FR  
09:56 - 10:09

13 / 16
## Scientific program

**EBMT-EHA 4th European CAR T-Cell Meeting February 10 - 12, 2022 Virtual**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>SS04-4</td>
<td>What were the other DLBCL highlights in CAR T from ASH?</td>
<td>10:09 - 10:20</td>
</tr>
<tr>
<td>Speaker: Sridhar Chaganti, GB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SS04Q</td>
<td>Close</td>
<td>10:20 - 10:23</td>
</tr>
</tbody>
</table>

**Break**  
10:30 - 11:00

**B5 - Break, Poster Viewing, Visit Exhibition**

**Physicians Session**  
11:00 - 12:15

**PS10 - Session 10 - How to set-up and run a CAR-T unit**  
*Chair: Ibrahim Yakoub-Agha, FR*  
*Chair: Natacha Bolaños, ES*

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>PS10-1</td>
<td>How to set-up and run a CAR-T unit</td>
<td>11:00 - 11:15</td>
</tr>
<tr>
<td>Speaker: Fabio Ciceri, IT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PS10-2</td>
<td>Patient communication</td>
<td>11:15 - 11:30</td>
</tr>
<tr>
<td>Speaker: Marie Jose Kersten, NL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PS10-3</td>
<td>Academic production</td>
<td>11:30 - 11:45</td>
</tr>
<tr>
<td>Speaker: Halvard Bönig, DE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PS10-4</td>
<td>Patient perspective</td>
<td>11:45 - 12:00</td>
</tr>
<tr>
<td>Speaker: Lorna Warwick, CA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PS10Q</td>
<td>Q&amp;A</td>
<td>12:00 - 12:15</td>
</tr>
</tbody>
</table>

**Physicians Session**  
11:00 - 12:15

**PS11 - Session 11 - Biotech Forum**  
*Chair: Ulf Grawunder, CH*  
*Chair: Michael Hudecek, DE*

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>PS11-1</td>
<td>The Inventor’s Perspective: Delivering CAR-Ts to the market</td>
<td>11:00 - 11:15</td>
</tr>
<tr>
<td>Speaker: Ulf Grawunder, CH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PS11-2</td>
<td>The Analysts’ Perspective: The CAR-T Market by 2030</td>
<td>11:15 - 11:30</td>
</tr>
</tbody>
</table>
| Speaker: Pemba Lahmo, IN  
Speaker: Rupali Chaudhary, IN |
| PS11-3  | Biotech showcase | 11:30 - 12:00 |
| Speaker: Armin Ehninger, DE  
Speaker: David Gilham, US  
Speaker: Ulf Grawunder, CH  
Speaker: Elisa Kieback, DE  
Speaker: Michael O’Dwyer, IE |
| PS11Q   | Q&A | 12:00 - 12:15 |
### Scientific Program

#### Best Abstracts

**BA03 - Best abstracts flash talks**

**Chair:** Hermann Einsele, DE  
**Chair:** Maria Themeli, NL

<table>
<thead>
<tr>
<th>BA03-1</th>
<th>N-glycosylation Inhibition Reverts Immunosuppression by TME Cells</th>
<th>12:20 - 12:25</th>
</tr>
</thead>
<tbody>
<tr>
<td>Speaker: Camilla Sirini, IT</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>BA03-2</th>
<th>Gene-transfer Methodology and Target-antigen Density Determine Car T-cell Performance</th>
<th>12:25 - 12:30</th>
</tr>
</thead>
<tbody>
<tr>
<td>Speaker: Leon Gehrke, DE</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>BA03-3</th>
<th>Dual CAR-CIK Cells for the Targeting of AML</th>
<th>12:30 - 12:35</th>
</tr>
</thead>
<tbody>
<tr>
<td>Speaker: Sarah Tettamanti, IT</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>BA03-4</th>
<th>Characterization of Antigen-driven CAR-T Cell Dysfunction in a Mouse Model of Her2-positive Solid Tumors</th>
<th>12:35 - 12:40</th>
</tr>
</thead>
<tbody>
<tr>
<td>Speaker: Paula Barbao, ES</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>BA03-5</th>
<th>Anti-CD117 CAR T Cells for Acute Myeloid Leukemia</th>
<th>12:40 - 12:45</th>
</tr>
</thead>
<tbody>
<tr>
<td>Speaker: Chiara F. Magnani, CH</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>BA03-6</th>
<th>ARI-0001 CART19 Cells in Relapsed/Refractory CLL and Richter’s Transformation</th>
<th>12:45 - 12:50</th>
</tr>
</thead>
<tbody>
<tr>
<td>Speaker: Valentin Ortiz-Maldonado, ES</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>BA03-7</th>
<th>AML Targeting via UniCAR T-cells</th>
<th>12:50 - 12:55</th>
</tr>
</thead>
<tbody>
<tr>
<td>Speaker: Laura Volta, CH</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>BA03Q</th>
<th>Q&amp;A</th>
<th>12:55 - 13:35</th>
</tr>
</thead>
</table>

#### Physicians Session

**PS12 - Session 12 - Trial management**

**Chair:** Stephan Mielke, SE  
**Chair:** Annalisa Ruggeri, IT

<table>
<thead>
<tr>
<th>PS12-1</th>
<th>European trial landscape</th>
<th>12:20 - 12:32</th>
</tr>
</thead>
<tbody>
<tr>
<td>Speaker: Álvaro Urbano Ispizu, ES</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PS12-2</th>
<th>Multinational trial experience</th>
<th>12:32 - 12:44</th>
</tr>
</thead>
<tbody>
<tr>
<td>Speaker: Julia Beckmann, DE</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PS12-3</th>
<th>Standardization in CAR-T trials</th>
<th>12:44 - 12:56</th>
</tr>
</thead>
<tbody>
<tr>
<td>Speaker: Hélène Negre, FR</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PS12-4</th>
<th>EBMT CAR-T Data base</th>
<th>12:56 - 13:08</th>
</tr>
</thead>
<tbody>
<tr>
<td>Speaker: Christian Chabannon, FR</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PS12-5</th>
<th>EBMT &amp; EHA GoCART Initiative</th>
<th>13:08 - 13:20</th>
</tr>
</thead>
<tbody>
<tr>
<td>Speaker: Jürgen Kuball, NL</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

|--------|--------|---------------|
Keynote
13:45 - 14:30

**KN04 - Keynote Lecture 4**

*Chair:* Anna Sureda, ES  
*Chair:* Elizabeth Macintyre, FR

**KN04-1**  
**CAR T Cells for Diffuse Midline Gliomas and Other Pediatric Solid Tumors**  
*Speaker:* Crystal Mackall, US

**KN04Q**  
**Q&A**
*Speaker:* Michael Hudecek, DE  
*Speaker:* Ibrahim Yakoub-Agha, FR

Physicians Session
14:30 - 14:45

**CLS - Closing remarks**

*Chair:* Ibrahim Yakoub-Agha, FR  
*Chair:* Michael Hudecek, DE